Objectives: This trial evaluated the efficacy of acetaminophen in reducing oxidative injury, as measured by plasma F 2 -isoprostanes, in adult patients with severe sepsis and detectable plasma cellfree hemoglobin. Design: Single-center, randomized, double-blind, placebo-controlled phase II trial. Setting: Medical ICU in a tertiary, academic medical center. Patients: Critically ill patients 18 years old or older with severe sepsis and detectable plasma cell-free hemoglobin. Interventions: Patients were randomized 1:1 to enteral acetaminophen 1 g every 6 hours for 3 days (n = 18) or placebo (n = 22) with the same dosing schedule and duration. Measurements and Main Results: F 2 -Isoprostanes on study day 3, the primary outcome, did not differ between acetaminophen (30 pg/mL; interquartile range, 24-41) and placebo (36 pg/ mL; interquartile range, 25-80; p = 0.35). However, F 2 -isoprostanes were significantly reduced on study day 2 in the acetaminophen group (24 pg/mL; interquartile range, 19-36) when compared with placebo (36 pg/mL; interquartile range, 23-55; p = 0.047). Creatinine on study day 3, a secondary outcome, was significantly lower in the acetaminophen group (1.0 mg/dL; interquartile range, 0.6-1.4) when compared with that in the placebo (1.3 mg/dL; interquartile range, 0.83-2.0; p = 0.039). There was no statistically significant difference in hospital mortality (acetaminophen 5.6% vs placebo 18.2%; p = 0.355) or adverse events (aspartate aminotransferase or alanine aminotransferase > 400; acetaminophen 9.5% vs placebo 4.3%; p = 0.599). Conclusions: In adults with severe sepsis and detectable plasma cell-free hemoglobin, treatment with acetaminophen within 24 hours of ICU admission may reduce oxidative injury and improve renal function. Additional study is needed to confirm these findings 535 and determine the effect of acetaminophen on patient-centered outcomes. (Crit Care Med 2015; 43:534-541) 
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Acetaminophen inhibits hemoprotein-mediated lipid peroxidation owing to its ability to reduce the iron protoporphyrin radical present within CFH (13, 14) . In animal studies, acetaminophen prevents oxidative injury and renal failure caused by rhabdomyolysis-induced release of the hemoprotein myoglobin (14) . In an observational study of adults with severe sepsis, we reported that acetaminophen administration was associated with reduced plasma levels of F 2 -IsoPs and was independently associated with decreased in-hospital mortality; this protective association was only observed in patients with detectable CFH (9) .
On the basis of these data suggesting that acetaminophen could reduce oxidative injury in patients with sepsis, we conducted a randomized, double-blind, placebo-controlled trial to test the primary hypothesis that the treatment of critically ill adults with severe sepsis and detectable plasma CFH with acetaminophen would decrease oxidative injury as measured by plasma F 2 -IsoPs. We further hypothesized that acetaminophen would improve renal function as measured by serum creatinine.
METHODS

Study Patients
Patients were enrolled from April 1, 2013, to December 21, 2013, in the Vanderbilt University Medical Center Medical ICU. The trial was approved by the Vanderbilt Institutional Review Board and was registered on www.clinicaltrials.gov (NCT01739361). Written informed consent was obtained from all patients or their surrogates. A data and safety monitor reviewed all adverse events and had access to all data as they were collected.
Patients with a diagnosis of severe sepsis as defined by consensus definitions (15, 16) were enrolled within 24 hours of ICU admission. Exclusion criteria included known use of acetaminophen in the previous 48 hours, history of intolerance or allergy to acetaminophen, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 400 U/L in the 24 hours prior to enrollment, history of chronic liver disease, patients not committed to full support, pregnancy or women of childbearing potential without a documented negative pregnancy test, patients unable to swallow and without enteral access, and patients whose treating team declined enrollment because of intended use or avoidance of acetaminophen.
Because acetaminophen selectively inhibits hemoproteinmediated lipid peroxidation, a finding supported in our observational study (9) , an initial blood sample was collected after enrollment and the plasma was tested for the presence of CFH using point-of-care testing with a HemoCue Plasma Low/Hb analyzer. Only patients with detectable CFH (≥ 10 mg/dL) were randomized. Once CFH was detected, patients immediately underwent randomization and study drug was started within 6 hours. Patients with undetectable CFH continued to be observed throughout the study period but were not randomized.
Treatment Assignments
Patients with severe sepsis and detectable CFH were randomly assigned in permuted blocks of four to receive either enteral acetaminophen 1 g every 6 hours for 3 days or identicalappearing placebo with the same schedule. The duration of 3 days was chosen using previous observational data in patients with sepsis (9) and data to suggest safety over this duration (17) . The dose of acetaminophen was chosen as the maximum Federal Drug Administration-approved dose and frequency allowed. Patients, care givers, and study personnel were blinded to the randomization scheme and group assignments during the entire study.
Measurements
Blood was collected on enrollment and in the morning of the subsequent 3 days. Blood samples were placed on ice and processed within 20 minutes of collection by centrifugation at 3,000 rpm for 10 minutes at 4°C, and then plasma was stored at -80°C. At the completion of the study, plasma F 2 -IsoPs, CFH, and acetaminophen were measured on enrollment and each study day. F 2 -Isofurans (F 2 -IsoFs), a marker of lipid peroxidation similar to F 2 -IsoPs but preferentially produced at high oxygen tensions (18) , were also measured as a secondary endpoint. F 2 -IsoP and F 2 -IsoF measurements were made using stable isotope dilution negative ion chemical ionization gas chromatography mass spectrometry (19) . Plasma from patients receiving propofol at the time of blood draw required an additional thin layer chromatography processing step to account for the lipid emulsion in propofol. CFH and acetaminophen were measured in duplicate using spectrophotometric methods (Quan-tiChrom Hemoglobin Assay Kit; Gentaur, San Jose, CA and Acetaminophen Test Kit; Fisher Scientific, Hanover Park, IL).
Statistical Analysis
The primary endpoint was plasma F 2 -IsoPs measured at the completion of the study (study day 3), after the last scheduled dose of study drug. Because the kidney is the most commonly reported target of oxidative injury by CFH (11, 14, 20) , renal function as measured by serum creatinine was a prespecified secondary endpoint. As this was a phase II study to determine whether acetaminophen has any effect on hemoprotein-mediated oxidative injury in severe sepsis, we developed a priori criteria required for a patient to be included in the primary analysis. These criteria included: the patient had to receive greater than or equal to four of 12 total doses of the study drug and had to have completed at least three of four total blood draws. We also prespecified an analysis of F 2 -IsoPs on study day 2 as a secondary endpoint given this study day marked completion of the a priori defined minimum protocol. Given past studies of F 2 -IsoPs in sepsis patients (9, 21) showing a difference of 60 pg/mL between patients who did and did not receive acetaminophen and an observed sd of 65 pg/mL, we calculated that we would need 40 patients in our primary analysis (20 in each arm) to have 80% power to detect this difference with an α of 0.05. Because we anticipated that 20% of patients with sepsis would not have detectable CFH, and that 5% would die prior to the third blood draw (9), we projected a total enrollment of 54 patients to achieve a sample size of 40 for inclusion in the primary endpoint analysis.
Data are expressed as median values with interquartile range (IQR) for continuous variables and frequencies for categorical variables. Between-group comparisons were conducted using the Wilcoxon rank-sum test for continuous variables, Fisher exact test for categorical variables, and Spearman rank correlation coefficient for correlation between two continuous variables. Kaplan-Meier survival curves were compared with the log-rank test. Linear regression was used to assess the influence of study group assignment and baseline F 2 -IsoP level on F 2 -IsoP level at completion of the study. Log transformation of variables was used in the setting of non-normally distributed residuals. IBM SPSS Statistics (version 22.0; Chicago, IL) was used for statistical analyses; a two-sided significance level of 0.05 was used for statistical inference.
RESULTS
A total of 245 patients with severe sepsis were screened, of whom 51 were enrolled in the study (Fig. 1) . The most common exclusion criteria were receipt of acetaminophen in the 48 hours prior to screening or chronic liver disease. An additional five patients were not randomized because of undetectable CFH levels (9.8%) or one had acetaminophen use in the interval between screening and enrollment (1.9%). Of the remaining 45 patients randomized, 40 patients (18 acetaminophen and 22 placebo) completed the a priori defined treatment protocol of at least four doses of study drug and three blood draws, which defined our primary study population. Of these 40 patients, nine did not have a fourth blood draw on study day 3 because of refusal of blood draw (n = 7) or discharge to another facility (n = 2).
Baseline Characteristics
At baseline, patients had similar severity of illness, number of organ failures, need for mechanical ventilation, and vasoactive medications ( Table 1) . Patients in the placebo group were older and had higher baseline levels of F 2 -IsoPs, IsoFs, and creatinine when compared with the acetaminophen group. Baseline levels of CFH were similar between groups. The lung (46%) and urinary tract (30%) were the most common sources of severe sepsis.
Efficacy of Acetaminophen on Oxidative Injury
In the 31 of 40 patients (77%) who had plasma samples available from study day 3, there was no significant difference in F 2 -IsoPs levels between the acetaminophen (30 pg/ mL; IQR, 24-41) and placebo groups (36 pg/mL; IQR, 25-80; p = 0.35) in a univariate analysis or when adjusted for baseline F 2 -IsoP levels (p = 0.21). However, on study day 2 when 39 of 40 patients had plasma samples available, there was a significant reduction in F 2 -IsoPs in the acetaminophen group (24 pg/mL; IQR, 19-36) compared with placebo (36 pg/mL; IQR, 23-55; p = 0.047) (Fig. 2) . Because plasma processing with an additional thin layer chromatography step for patients who were receiving propofol at the time of blood draw could introduce systematic differences in measured F 2 -IsoP levels, we performed a sensitivity analysis after removing the patients who were receiving propofol at the time of blood draw (n = 5 on both study days 2 and 3: three patients in placebo group and two patients in acetaminophen group). There remained a statistically significant decrease in F 2 -IsoPs in the acetaminophen group on day 2 (23 pg/mL; IQR, 18-36) compared with placebo (42 pg/mL; IQR, 23-73; p = 0.016), and the difference in F 2 -IsoPs on study day 3 approached significance (30 pg/mL; IQR, 23-39) compared with placebo (49 pg/mL; IQR, 26-86; p = 0.058). There was no difference in F 2 -IsoF levels on study day 2 or 3 between the acetaminophen and the placebo groups; however, when patients receiving propofol were removed from the analysis, there was a significant reduction in F 2 -IsoF levels on study day 3 in the acetaminophen group (27 pg/mL; IQR, 20-49) compared with placebo (57 pg/mL; IQR, 42-83; p = 0.029) (Fig. 2) . Serum creatinine was significantly lower in the acetaminophen group on study day 3 (1.04 mg/dL; IQR, 0.61-1.44) compared with placebo (1.36 mg/dL; IQR, 0.83-2.02; p = 0.039). This difference persisted after completion of the study drug at Figure 2 . Plasma F 2 -isoprostanes and F 2 -isofurans measured at baseline and each study day. F 2 -Isoprostane and F 2 -isofuran levels were compared between groups on each study day (A and B) and in patients who were not receiving propofol at the time of blood draw (C and D) to account for differences in sample processing with this group of patients. Values of p represent between-group comparisons at each time point. Study day 3 was the primary endpoint of the study, and study day 2 was analyzed as a secondary endpoint. Squares and circles represent medians, and bars represent interquartile ranges. day 4 (0.93 mg/dL; IQR, 0.55-1.2 vs 1.3 mg/dL; IQR, 0.97-3.45; p = 0.004), for the highest creatinine measured during the remainder of hospitalization, and for creatinine measured on the day of discharge or death. After removing the four patients from the analysis whose creatinine levels were manipulated by renal replacement therapy at any point during the study (three in placebo group and one in acetaminophen group), this significant reduction of creatinine in the acetaminophen group during and after the study period persisted (Fig. 3) . In a linear regression model controlling for baseline creatinine, acetaminophen significantly reduced creatinine at study day 3 (β = -0.48; 95% CI, -0.86 to -0.1; p = 0.014). In agreement with past animal studies (11), we found that increased baseline CFH correlated strongly with subsequent creatinine after completion of the study (r s = 0.427; p = 0.009). Acetaminophen attenuated this response to baseline CFH. When controlling for baseline CFH levels, patients in the acetaminophen group had significantly lower creatinine on study day 3 and 4 when compared with placebo (β = -0.5; 95% CI, -0.95 to -0.06; p = 0.027 and β = -1.17; 95% CI, -2.1 to -0.15; p = 0.026, respectively).
Effect of Acetaminophen on Other Clinical Endpoints
Acetaminophen modestly but significantly decreased the maximum temperature observed on study day 3 (36.9°C; IQR, 36.9-37.1) compared with placebo (37.1°C; IQR, 36.9-37.4; p = 0.049). There were no significant differences between groups during the study period in heart rate or mean arterial blood pressure. By study day 3, there were more patients alive and free of organ failures in the acetaminophen group versus placebo (55% vs 30%; p = 0.18), but this difference was not significant. Differences in ventilator-free days (acetaminophen 28 d, IQR, 23-28 vs placebo 27 d, IQR, 20-28; p = 0.527) and in-hospital mortality (acetaminophen 5.6% vs placebo 18.2%; p = 0.355) were also not significantly different between groups (Fig. 4) .
Protocol Adherence and Adverse Events
Acetaminophen was detectable and significantly increased in the plasma of the acetaminophen group on every study day after enrollment when compared with the placebo group (Fig. 5) . Among the 40 patients in the primary analysis, seven acetaminophen patients (38%) and 10 placebo patients (45%) missed any dose of study drug (p = 0.75) with a median number of doses missed of 2 (IQR, 1-5). Missed doses were because of nothing by mouth status (42%), inability to swallow with a lack of enteral access (35%), and patient refusal (23%). No off-protocol acetaminophen was received by any patient during the 3-day study period.
Although the primary analysis included 40 patients who were able to complete the a priori defined protocol, adverse event data were collected on all patients exposed to any amount Figure 3 . Creatinine measured at enrollment, each study day, and after study completion in patients never requiring renal replacement therapy. In patients never receiving any type of renal replacement therapy during or after the study (n = 36), creatinine levels were similar at baseline (study day 0) and were significantly reduced in the acetaminophen group on study day 3, the day following study completion (day 4), through the remainder of hospitalization and at discharge or death. Values of p represent between-group comparisons at each time point. Squares and circles represent medians, and bars represent interquartile ranges. of study drug. Among these 44 patients, there was no occurrence of rash or other hypersensitivity. AST and ALT were recorded if measured for clinical purposes; however, measurement of AST and ALT was not a mandated part of the study because the dose used in this study is approved by the Food and Drug Administration and has a good safety profile (17) . Of the patients who were exposed to any amount of study drug and who had AST or ALT measured as part of their routine ICU care, there were two patients(9.5%) in the acetaminophen group and one in the placebo group (4.3%) (p = 0.599) who had a new AST or ALT elevation above 400 U/L after enrollment. Among the 40 patients in the primary analysis who received greater than or equal tofour doses of study drug, the median highest measured AST at the completion of the study in the acetaminophen group (75 U/L, IQR, 24-75) or during the remainder of the patients hospitalization (29 U/L; IQR, 25-184) was not statistically different from placebo (study completion, 49 U/L; IQR, 42-410; p = 0.699 and remainder of hospitalization, 49 U/L; IQR, 21-101; p = 0.934).
DISCUSSION
This randomized, double-blind, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in patients with severe sepsis and detectable CFH demonstrated that acetaminophen may reduce oxidative injury as measured by plasma levels of F 2 -IsoPs and IsoFs and was effective in decreasing creatinine compared with placebo. Although levels of F 2 -IsoPs were not different at day 3, this analysis included fewer patients (n = 31) than the analysis at day 2 (n = 39), which showed a significant reduction of F 2 -IsoPs with acetaminophen.
CFH can be detected in the plasma in a number of disease states, such as sickle cell-anemia (1), malaria (20) , patients undergoing hemodialysis (2), cardiac bypass (3, 4) , and red blood cell transfusion (5) . In all of these patient populations, CFH has been associated with poor clinical outcomes thought to be mediated by the propensity of CFH to scavenge nitric oxide (1, 2, 5, 7, 8) and damage the vascular endothelium (11) , as well as the detrimental ability of the iron moiety of CFH to oxidize lipid membranes and release F 2 -IsoPs and IsoFs (3, 12) . CFH-related iron deposition and production of the highly vasoconstrictive F 2 -IsoPs and IsoFs is thought to be the primary mechanism of renal injury in CFH and other hemoproteinmediated disease states (11, 12, 20) such as rhabdomyolysis.
Acetaminophen, at therapeutic concentrations, is a potent inhibitor of hemoprotein-mediated lipid peroxidation owing to its ability to reduce the ferryl radical present in CFH (13) . This reductive capacity of acetaminophen inhibits the ability of CFH to cause oxidative damage and induce organ injury. In an animal model of rhabdomyolysis leading to acute kidney injury induced by the hemoprotein myoglobin, animals treated with acetaminophen had reduced F 2 -IsoPs and creatinine levels and improved creatinine clearance (14) .
Sepsis is characterized, in part, by oxidant injury (21) , kidney injury (22) , and high mortality (23, 24) . Animal models of sepsis support CFH as a mediator of morbidity and mortality; in these models end-organ damage and risk of mortality could be attenuated by rescue therapies directed at CFH (25) . Using observational data, we (9) and others (10) have recently described CFH as a potential injurious mediator in humans with sepsis, the presence of which is associated with oxidative injury and increased mortality. We also reported that acetaminophen use in patients with sepsis was associated with lower plasma levels of F 2 -IsoPs and was independently associated with decreased in-hospital mortality in patients with detectable CFH (9) .
The current randomized trial suggests that acetaminophen may reduce oxidative and renal injury in patients with sepsis and detectable CFH. Although there was no significant difference in the primary outcome of F 2 -IsoP on study day 3, the analysis of the secondary outcome of patients on study day 2 showed a significant reduction in F 2 -IsoP in the acetaminophen group. There are a number of possible explanations for the discrepant findings at day 2 and day 3. First, the study day 3 analysis was underpowered to detect a difference with eight patients missing from the analysis compared with study day 2 and the original study power analysis may have overestimated the anticipated effect size. Second, the additional thin layer chromatography step required for patients receiving propofol may have introduced a systematic bias into the F 2 -IsoP measurements. However, removing patients receiving propofol from the analysis did not change the study results significantly. Although there was no substantial change in the F 2 -IsoP analysis after removing patients receiving propofol, we cannot predict how the inclusion or exclusion of these patients in future, larger trials will affect F 2 -IsoP analysis. Third, acetaminophen might have an early effect on F 2 -IsoPs that is not durable in patients with multiple potential sources of oxidative injury. Finally, it is possible that acetaminophen may lack efficacy in reducing F 2 -IsoPs and any difference only reflects a baseline imbalance. Potentially of greater clinical relevance was the robust and consistent reduction in creatinine seen in the acetaminophen group, which is in agreement with past animal studies (14) , and was consistent across a number of different analyses. Because even small elevations of creatinine are common in sepsis and associated with substantially increased morbidity and mortality (22, 26) , new therapies for this complication are needed.
The current trial has some limitations. First, the small sample size, single-center, and surrogate endpoints limit the generalizability of the results. Second, there were baseline imbalances in age, creatinine, and F 2 -IsoP levels, which may influence the results. The safety profile of acetaminophen at this dose and schedule appears to be acceptable in regards to laboratory values and clinical outcomes in critically ill adults with severe sepsis; however, AST and ALT monitoring was not mandated in the protocol that may reduce the sensitivity of detecting adverse events. Finally, this trial was conducted only in medical ICU patients with severe sepsis, limiting the generalizability of the data to other patient populations.
This trial may have a number of implications for future research in critically ill patients with sepsis. Enteral acetaminophen is a common, inexpensive, and easily administered drug with an acceptable safety profile during short-term use in healthy subjects (17) and in the current study of critically ill patients with severe sepsis. Although the reduction in biomarkers of oxidative injury in the study was not consistent across all analyses, the biologic plausibility of benefit with acetaminophen in patients with sepsis and detectable CFH, ease and safety of administration, consistent although nonsignificant improvement across all clinical outcomes, and the finding of improved renal function should warrant a larger trial in this patient population.
CONCLUSIONS
Although there was no significant reduction in plasma levels of F 2 -IsoPs in the acetaminophen group on study day 3, acetaminophen significantly improved F 2 -IsoPs at day 2 compared with placebo and improved renal function during and after the completion of the study in 40 patients with severe sepsis. Additional study with larger sample sizes and heterogeneous patient populations is warranted to determine whether acetaminophen improves important clinical outcomes such as incidence of acute kidney injury and mortality in patients with severe sepsis.
